AB Science partners with Skuldtech for pancreatic cancer companion Dx
This article was originally published in Clinica
Executive Summary
French biopharma firm AB Science and genomic company Skuldtech are developing a companion diagnostic which would identify patients who respond best to masitinib, AB Science's new drug therapy for pancreatic cancer. The test is based on a novel set of biomarkers that were discovered during a Phase III clinical trial evaluating the therapeutic efficacy of a combined masitinib/gemcitabine therapy with the current standard pancreatic cancer treatment of gemcitabine alone.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.